India · Delayed Price · Currency is INR Ajooni Biotech Statistics
Total Valuation
Ajooni Biotech has a market cap or net worth of INR 659.69 million. The enterprise value is 833.13 million.
| Market Cap | 659.69M |
| Enterprise Value | 833.13M |
Important Dates
The last earnings date was Thursday, May 28, 2026.
| Earnings Date | May 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Ajooni Biotech has 172.24 million shares outstanding. The number of shares has increased by 0.37% in one year.
| Current Share Class | 172.24M |
| Shares Outstanding | 172.24M |
| Shares Change (YoY) | +0.37% |
| Shares Change (QoQ) | +14.95% |
| Owned by Insiders (%) | 17.59% |
| Owned by Institutions (%) | n/a |
| Float | 129.84M |
Valuation Ratios
The trailing PE ratio is 15.32.
| PE Ratio | 15.32 |
| Forward PE | n/a |
| PS Ratio | 0.36 |
| PB Ratio | 0.72 |
| P/TBV Ratio | 0.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 19.28 |
| EV / Sales | 0.45 |
| EV / EBITDA | 9.60 |
| EV / EBIT | 12.88 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.72, with a Debt / Equity ratio of 0.19.
| Current Ratio | 2.72 |
| Quick Ratio | 0.69 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 2.05 |
| Debt / FCF | -0.75 |
| Interest Coverage | 8.87 |
Financial Efficiency
Return on equity (ROE) is 4.82% and return on invested capital (ROIC) is 4.65%.
| Return on Equity (ROE) | 4.82% |
| Return on Assets (ROA) | 3.75% |
| Return on Invested Capital (ROIC) | 4.65% |
| Return on Capital Employed (ROCE) | 6.95% |
| Weighted Average Cost of Capital (WACC) | 5.42% |
| Revenue Per Employee | 13.79M |
| Profits Per Employee | 322,530 |
| Employee Count | 134 |
| Asset Turnover | 1.72 |
| Inventory Turnover | 4.66 |
Taxes
In the past 12 months, Ajooni Biotech has paid 14.16 million in taxes.
| Income Tax | 14.16M |
| Effective Tax Rate | 24.68% |
Stock Price Statistics
The stock price has decreased by -31.62% in the last 52 weeks. The beta is 0.33, so Ajooni Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -31.62% |
| 50-Day Moving Average | 4.14 |
| 200-Day Moving Average | 4.57 |
| Relative Strength Index (RSI) | 39.45 |
| Average Volume (20 Days) | 348,202 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ajooni Biotech had revenue of INR 1.85 billion and earned 43.22 million in profits. Earnings per share was 0.25.
| Revenue | 1.85B |
| Gross Profit | 368.68M |
| Operating Income | 64.68M |
| Pretax Income | 57.38M |
| Net Income | 43.22M |
| EBITDA | 86.74M |
| EBIT | 64.68M |
| Earnings Per Share (EPS) | 0.25 |
Balance Sheet
The company has 4.19 million in cash and 177.63 million in debt, with a net cash position of -173.44 million or -1.01 per share.
| Cash & Cash Equivalents | 4.19M |
| Total Debt | 177.63M |
| Net Cash | -173.44M |
| Net Cash Per Share | -1.01 |
| Equity (Book Value) | 911.92M |
| Book Value Per Share | 4.81 |
| Working Capital | 471.29M |
Cash Flow
In the last 12 months, operating cash flow was -57.34 million and capital expenditures -180.28 million, giving a free cash flow of -237.62 million.
| Operating Cash Flow | -57.34M |
| Capital Expenditures | -180.28M |
| Depreciation & Amortization | 22.06M |
| Net Borrowing | 158.23M |
| Free Cash Flow | -237.62M |
| FCF Per Share | -1.38 |
Margins
Gross margin is 19.95%, with operating and profit margins of 3.50% and 2.34%.
| Gross Margin | 19.95% |
| Operating Margin | 3.50% |
| Pretax Margin | 3.11% |
| Profit Margin | 2.34% |
| EBITDA Margin | 4.69% |
| EBIT Margin | 3.50% |
| FCF Margin | n/a |
Dividends & Yields
Ajooni Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.37% |
| Shareholder Yield | -0.37% |
| Earnings Yield | 6.55% |
| FCF Yield | -36.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 7, 2022. It was a forward split with a ratio of 5.
| Last Split Date | Oct 7, 2022 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |